US stocks starting with K
The official accounts of 64 companies listed in the United States whose name starts with K: revenue and net profit for the latest fiscal year, as stated in the annual report (Form 10-K) each one files with the SEC, in US dollars. Each one links to its page, with the document every figure comes from.
| Company | Ticker | Fiscal year | Revenue | Net profit |
|---|---|---|---|---|
| Kadant | NYSE: KAI | 2025 | $1,052m | $102.0m |
| Kaiser Aluminum | NASDAQ: KALU | 2025 | $3,373m | $112.5m |
| Kaltura | NASDAQ: KLTR | 2025 | $180.9m | −$12.1m |
| Karat Packaging | NASDAQ: KRT | 2025 | $467.7m | $31.5m |
| Karman | NYSE: KRMN | 2025 | $471.5m | $17.4m |
| Karyopharm Therapeutics | NASDAQ: KPTI | 2025 | $146.1m | −$196.0m |
| Kayne Anderson BDC | NYSE: KBDC | 2025 | — | $93.7m |
| KB Home | NYSE: KBH | 2025 | $6,236m | $428.8m |
| KBR | NYSE: KBR | 2025 | $7,786m | $415.0m |
| Kearny Financial | NASDAQ: KRNY | 2026 | $178.1m | $36.3m |
| Kelly Services | NASDAQ: KELYA | 2025 | $4,251m | −$254.1m |
| Kemper | NYSE: KMPR | 2025 | $4,790m | $143.3m |
| Kennametal | NYSE: KMT | 2026 | $2,357m | $342.4m |
| Kenvue | NYSE: KVUE | 2025 | $15,124m | $1,470m |
| Keros Therapeutics | NASDAQ: KROS | 2025 | $244.1m | $87.0m |
| Kestra Medical Technologies | NASDAQ: KMTS | 2026 | $95.1m | −$131.6m |
| Keurig Dr Pepper | NASDAQ: KDP | 2025 | $16,603m | $2,079m |
| KeyCorp | NYSE: KEY | 2025 | $7,513m | $1,829m |
| Keysight Technologies | NYSE: KEYS | 2025 | $5,375m | $850.0m |
| Kforce | NYSE: KFRC | 2025 | $1,329m | $34.8m |
| Kilroy Realty | NYSE: KRC | 2025 | $1,113m | $302.6m |
| Kimball Electronics | NASDAQ: KE | 2026 | $1,431m | $28.0m |
| Kimbell Royalty Partners | NYSE: KRP | 2025 | $333.8m | $99.7m |
| Kimberly-Clark | NASDAQ: KMB | 2025 | $16,447m | $2,021m |
| Kimco Realty | NYSE: KIM | 2025 | $2,140m | $584.7m |
| Kinder Morgan | NYSE: KMI | 2025 | $16,937m | $3,056m |
| KinderCare Learning Companies | NYSE: KLC | 2025 | $2,733m | −$112.9m |
| Kinetik | NYSE: KNTK | 2025 | $1,764m | $178.3m |
| Kingstone Companies | NASDAQ: KINS | 2025 | $214.9m | $40.8m |
| Kingsway | NYSE: KWY | 2025 | $135.0m | −$10.3m |
| Kiniksa Pharmaceuticals International | NASDAQ: KNSA | 2025 | $677.6m | $59.0m |
| Kinsale Capital Group | NYSE: KNSL | 2025 | $1,874m | $503.6m |
| Kirby | NYSE: KEX | 2025 | $3,364m | $354.6m |
| Kite Realty Group Trust | NYSE: KRG | 2025 | $844.4m | $298.7m |
| KKR | NYSE: KKR | 2025 | $19,464m | $2,370m |
| KKR Real Estate Finance Trust | NYSE: KREF | 2025 | $435.6m | −$47.1m |
| KLA | NASDAQ: KLAC | 2026 | $13,579m | $4,831m |
| Klaviyo | NYSE: KVYO | 2025 | $1,234m | −$31.8m |
| Knife River | NYSE: KNF | 2025 | $3,146m | $157.1m |
| Knight-Swift Transportation | NYSE: KNX | 2025 | $7,470m | $65.9m |
| Knowles | NYSE: KN | 2025 | $593.2m | $44.2m |
| Kodiak Gas Services | NYSE: KGS | 2025 | $1,308m | $80.5m |
| Kodiak Sciences | NASDAQ: KOD | 2025 | — | −$230.0m |
| Kohl’S | NYSE: KSS | 2026 | $15,527m | $272.0m |
| Kontoor Brands | NYSE: KTB | 2025 | $3,152m | $227.5m |
| Kopin | NASDAQ: KOPN | 2025 | $39.3m | $2.6m |
| Koppers | NYSE: KOP | 2025 | $1,879m | $56.0m |
| Korn Ferry | NYSE: KFY | 2026 | $2,939m | $277.4m |
| Korro Bio | NASDAQ: KRRO | 2025 | $6.4m | −$117.3m |
| Koru Medical Systems | NASDAQ: KRMD | 2025 | $41.1m | −$2.6m |
| Kosmos Energy | NYSE: KOS | 2025 | $1,288m | −$699.8m |
| Kraft Heinz | NYSE: KHC | 2025 | $24,942m | −$5,846m |
| Kratos Defense & Security Solutions | NASDAQ: KTOS | 2025 | $1,347m | $22.0m |
| Krispy Kreme | NASDAQ: DNUT | 2025 | $1,523m | −$515.8m |
| Kroger | NYSE: KR | 2026 | $147,642m | $1,016m |
| Kronos Worldwide | NYSE: KRO | 2025 | $1,859m | −$110.9m |
| Krystal Biotech | NASDAQ: KRYS | 2025 | $389.1m | $204.8m |
| Kulicke and Soffa Industries | NASDAQ: KLIC | 2025 | $654.1m | $0.2m |
| Kura Oncology | NASDAQ: KURA | 2025 | $67.5m | −$278.7m |
| Kura Sushi USA | NASDAQ: KRUS | 2026 | $328.3m | −$4.6m |
| KVH Industries | NASDAQ: KVHI | 2025 | $111.0m | −$7.4m |
| Kymera Therapeutics | NASDAQ: KYMR | 2025 | $39.2m | −$311.4m |
| Kyndryl | NYSE: KD | 2026 | $15,092m | $198.0m |
| Kyverna Therapeutics | NASDAQ: KYTX | 2025 | — | −$161.3m |
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell.